

**BCHE Antibody (Center) Blocking Peptide**  
Synthetic peptide  
Catalog # BP7829c**Specification**

---

**BCHE Antibody (Center) Blocking Peptide - Product Information**Primary Accession [P06276](#)**BCHE Antibody (Center) Blocking Peptide - Additional Information**

Gene ID 590

**Other Names**

Cholinesterase, Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, Pseudocholinesterase, BCHE, CHE1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7829c](/products/AP7829c) was selected from the Center region of human BCHE. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**BCHE Antibody (Center) Blocking Peptide - Protein Information**

Name BCHE

Synonyms CHE1

**Function**

Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.

**Cellular Location**

Secreted

**Tissue Location**

Detected in blood plasma (at protein level). Present in most cells except erythrocytes

## **BCHE Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **BCHE Antibody (Center) Blocking Peptide - Images**

## **BCHE Antibody (Center) Blocking Peptide - Background**

Mutant proteins of BCHE are responsible for suxamethonium sensitivity. Homozygous persons sustain prolonged apnea after administration of the muscle relaxant suxamethonium in connection with surgical anesthesia. The activity of pseudocholinesterase in the serum is low and its substrate behavior is atypical. In the absence of the relaxant, the homozygote is at no known disadvantage.

## **BCHE Antibody (Center) Blocking Peptide - References**

Primo-Parmo S.L., Bartels C.F. Am. J. Hum. Genet. 58:52-64(1996) Primo-Parmo S.L., Lightstone H. Pharmacogenetics 7:27-34(1997) Yen T., Nightingale B.N. Clin. Chem. 49:1297-1308(2003)